Compare Stocks

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNSP CNS Pharmaceuticals	$0.19 -9.4%	$0.28	$0.19 ▼ $2.98	$2.04M	2.78	373,026 shs	187,078 shs
DRMA Dermata Therapeutics	$0.33 -2.9%	$0.38	$0.23 ▼ $2.81	$2.20M	0.89	600,145 shs	112,752 shs
NTBL Notable Labs	$1.08 -1.8%	$1.34	$0.83 ▼ $11.20	$2.40M	0.93	360,864 shs	67,508 shs
SLRX Salarius Pharmaceuticals	$0.46	$0.53	$0.43 ▼ $1.87	$2.19M	0.95	87,154 shs	14,594 shs

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNSP CNS Pharmaceuticals	-7.51%	-19.96%	-19.76%	-32.12%	-84.51%
DRMA Dermata Therapeutics	-2.94%	+1.04%	+9.93%	-29.03%	-87.31%
NTBL Notable Labs	-1.82%	-9.24%	-8.47%	-8.47%	+107,999,900.00%
SLRX Salarius Pharmaceuticals	+0.64%	-5.99%	-8.40%	-22.37%	-67.29%

This Wall Street stock prediction just went viral (Ad)

People around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And he just issued an urgent WARNING for some of the most popular stocks in U.S. history.

Watch just the first 5 minutes of his new prediction

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NTBL Notable Labs	3.4101 of 5 stars	3.5	5.0	0.0	0.0	3.7	1.7	0.6
SLRX Salarius Pharmaceuticals	1.0956 of 5 stars	0.0	5.0	0.0	0.0	2.9	0.0	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A
NTBL Notable Labs	3.00	Buy	$8.00	640.74% Upside
SLRX Salarius Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings

Latest NTBL, SLRX, CNSP, and DRMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/15/2024	NTBL Notable Labs	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00
4/15/2024	NTBL Notable Labs	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $7.00

(Data available from 5/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	($0.71) per share	N/A
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	$1.62 per share	N/A
NTBL Notable Labs	$310K	7.73	N/A	N/A	$6.81 per share	0.16
SLRX Salarius Pharmaceuticals	$1.84M	1.19	N/A	N/A	$1.34 per share	0.34

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNSP CNS Pharmaceuticals	-$18.85M	-$5.66	N/A	∞	N/A	N/A	-603.40%	-421.35%	5/20/2024 (Estimated)
DRMA Dermata Therapeutics	-$7.80M	-$3.65	N/A	∞	N/A	N/A	-107.95%	-93.59%	5/16/2024 (Estimated)
NTBL Notable Labs	-$11.26M	-$3.63	N/A	∞	N/A	N/A	-62.07%	-48.32%	5/20/2024 (Estimated)
SLRX Salarius Pharmaceuticals	-$12.54M	-$2.71	N/A	N/A	N/A	N/A	-135.21%	-98.91%	8/8/2024 (Estimated)

Latest NTBL, SLRX, CNSP, and DRMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/1/2024	Q4 2023	CNSP CNS Pharmaceuticals	N/A	-$0.95	-$0.95	-$0.95	N/A	N/A
3/22/2024	Q4 2023	SLRX Salarius Pharmaceuticals	-$1.01	-$0.22	+$0.79	-$0.22	N/A	N/A
3/21/2024	Q4 2023	DRMA Dermata Therapeutics	N/A	-$0.21	-$0.21	-$0.21	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	N/A
NTBL Notable Labs	N/A	N/A	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNSP CNS Pharmaceuticals	N/A	0.26	0.26
DRMA Dermata Therapeutics	N/A	4.91	4.91
NTBL Notable Labs	0.02	5.65	5.65
SLRX Salarius Pharmaceuticals	N/A	5.02	5.02

Ownership

Institutional Ownership

Company	Institutional Ownership
CNSP CNS Pharmaceuticals	14.02%
DRMA Dermata Therapeutics	8.67%
NTBL Notable Labs	70.48%
SLRX Salarius Pharmaceuticals	11.88%

Insider Ownership

Company	Insider Ownership
CNSP CNS Pharmaceuticals	9.20%
DRMA Dermata Therapeutics	4.30%
NTBL Notable Labs	1.20%
SLRX Salarius Pharmaceuticals	3.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CNSP CNS Pharmaceuticals	3	10.64 million	9.66 million	Not Optionable
DRMA Dermata Therapeutics	8	6.66 million	6.38 million	Not Optionable
NTBL Notable Labs	13	2.22 million	2.19 million	No Data
SLRX Salarius Pharmaceuticals	2	4.78 million	4.61 million	Not Optionable

NTBL, SLRX, CNSP, and DRMA Headlines

Recent News About These Companies

May 14 at 12:08 AM | investorplace.com

SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024

May 13 at 5:05 PM | timesunion.com

Salarius: Q1 Earnings Snapshot

May 11, 2024 | americanbankingnews.com

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Sees Significant Decrease in Short Interest

April 2, 2024 | finance.yahoo.com

SLRX Pursues Important Goal

March 27, 2024 | msn.com

Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data

March 25, 2024 | msn.com

Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket

March 23, 2024 | finanznachrichten.de

Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 22, 2024 | sfgate.com

Salarius: Q4 Earnings Snapshot

March 22, 2024 | globenewswire.com

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 5, 2024 | msn.com

Quoin stock craters 47% on public offering after rallying in prior session

March 4, 2024 | msn.com

Quoin stock soars 60% on FDA update for ichthyosis drug

February 22, 2024 | markets.businessinsider.com

Salarius Pharmaceuticals Implements Cost-savings Measures

February 22, 2024 | msn.com

Salarius's CEO David Arthur steps down

February 22, 2024 | finance.yahoo.com

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

February 9, 2024 | uk.investing.com

Salarius Pharmaceuticals Inc (SLRX)

January 16, 2024 | finance.yahoo.com

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

January 13, 2024 | wsj.com

Square Pharmaceuticals Ltd.

January 3, 2024 | finance.yahoo.com

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

November 10, 2023 | finance.yahoo.com

SLRX Continues Work as it Seeks Alternatives

November 8, 2023 | morningstar.com

Salarius Pharmaceuticals Inc SLRX

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CNS Pharmaceuticals

NASDAQ:CNSP

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Dermata Therapeutics

NASDAQ:DRMA

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Notable Labs

NASDAQ:NTBL

Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.

Salarius Pharmaceuticals

NASDAQ:SLRX

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial